Enrollment of
56 patients with male pattern hair loss in the Phase I/II clinical trial of HSC has been completed, and the trial is ongoing. Dr. Gail Naughton, Histogen CEO and Chairman of the Board, presented the 12 week primary safety and efficacy data at the Society for Investigative Dermatology (SID) Annual Meeting on May 11, 2012.
Sounds like most of the patients were men (
http://www.histogen.com/applications/hsc.htm)
Bookmarks